

Importance of the gut microbiota in the gut-liver axis in normal and liver disease

Stanislav Kotlyarov

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Zhang JW, China

Received: March 3, 2024

Revised: May 1, 2024

Accepted: May 17, 2024

Published online: June 27, 2024

Processing time: 108 Days and 17.3 Hours



Stanislav Kotlyarov, Department of Nursing, Ryazan State Medical University, Ryazan 390026, Russia

Corresponding author: Stanislav Kotlyarov, PhD, Academic Research, Department of Nursing, Ryazan State Medical University, Vysokovoltnaya St. 9, Ryazan 390026, Russia.
skmr1@yandex.ru

Abstract

The gut microbiota is of growing interest to clinicians and researchers. This is because there is a growing understanding that the gut microbiota performs many different functions, including involvement in metabolic and immune processes that are systemic in nature. The liver, with its important role in detoxifying and metabolizing products from the gut, is at the forefront of interactions with the gut microbiota. Many details of these interactions are not yet known to clinicians and researchers, but there is growing evidence that normal gut microbiota function is important for liver health. At the same time, factors affecting the gut microbiota, including nutrition or medications, may also have an effect through the gut-liver axis.

Key Words: Gut microbiota; Liver; Gut-liver axis; Immunity; Non-alcoholic fatty liver disease

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The gut microbiota plays an important immune and metabolic role in the body both under physiologic conditions and in the development of various liver diseases. The gut microbiota is involved in the production of various substances such as short-chain fatty acids, which play an important role in linking the gut to other organs. The composition of the gut microbiota may change in various liver diseases, and this relationship is two-way.

Citation: Kotlyarov S. Importance of the gut microbiota in the gut-liver axis in normal and liver disease. *World J Hepatol* 2024; 16(6): 878-882

URL: <https://www.wjgnet.com/1948-5182/full/v16/i6/878.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v16.i6.878>

INTRODUCTION

The gut microbiota is a subject of increasing interest to clinicians and researchers due to the growing body of new data on its important metabolic and immune roles in the organism[1-4]. The human gastrointestinal tract is continuously colonized by a vast array of microorganisms, including bacteria, archaea, fungi, and viruses, and the number of these microorganisms is estimated to be comparable to or significantly greater than the number of human cells[5-7]. It is estimated that the microbiota's collective genome may contain 100 times more genes than the human genome[8-10]. Of course, these microorganisms are closely related to the human body. The gut microbiota population is known to be dominated by anaerobic bacteria, with 90% of the gut microbiota consisting of Bacteroidetes (Gram-negative) and Firmicutes (Gram-positive), followed by Actinobacteria (Gram-positive) and Proteobacteria (Gram-negative)[11,12].

The relationship between macroorganisms and microbiota has deep evolutionary roots and is well-known in animals. This symbiotic relationship serves many important physiological purposes, including the participation of bacteria in the digestion of food substances that are inaccessible to macroorganism digestive enzymes, as well as the synthesis of substances required by the macroorganism and participation in immune mechanisms. The gut microbiota produces metabolites such as short-chain fatty acids (SCFAs)[13,14]. The three primary SCFAs are acetate, propionate, and butyrate. These SCFAs are formed from dietary fibers such as resistant starch, cellulose, and pectin. SCFAs serve as an energy source for the intestinal epithelium and also enter the bloodstream through the portal vein, where they participate in various processes, including immune mechanisms. SCFA play a role in regulating immune cell activation in various organs, including the liver[13]. Butyrate, for instance, promotes the functional maturation of liver-resident natural killer cells in the liver by acting through hepatocytes and Kupffer cells[15]. Furthermore, the gut microbiota has been linked to liver regeneration[16]. During hepatectomy, the gut microbiota is associated with hepatocyte proliferation through the activity of CD1d-dependent natural T-killer and Kupffer cells[17,18].

The gut microbiome of mammals and humans is highly diverse, consisting of thousands of known species. Dietary patterns significantly impact this diversity. Studies have demonstrated that alterations in dietary patterns, both in humans and animals, can modify the composition of the gut microbiota. Research has shown that mice fed a Western diet experienced a decrease in Bacteroidetes and an increase in Firmicutes in their gut compared to normal mice[19,20]. Similarly, captive great apes have a different microbiota profile compared to their wild counterparts, which is similar to the microbiome of humans from non-urbanized societies. Furthermore, obesity has been linked to changes in the composition of the gut microbiota. The proportion of Bacteroidetes has been found to decrease in obese individuals compared to those who are lean. However, this proportion has been shown to increase with weight loss on two types of low-calorie diets[21]. It is worth noting that bariatric surgery also impacts the composition of the gut microbiota, which is an area of increasing interest[22].

The human body has mechanisms that promote microbial colonization of the gut and mechanisms to control this microbial population. The intestinal microbiome is a complex regulated system that is closely related to the human body. For example, goblet cells produce mucus that contains mucins and has two layers that separate bacteria from underlying intestinal epithelial cells[11]. The layers have a comparable protein composition, which includes the gel-forming mucin Muc2 as a significant structural component[23]. Additionally, the inner mucus layer is tightly packed, immobile relative to the epithelium, and free of bacteria, while the outer mucus layer is mobile, colonized by bacteria, and has a larger volume due to proteolytic cleavage of Muc2 mucin. The spatial separation of bacteria and the intestinal epithelium is maintained by antibacterial substances secreted by the epithelium and secretory immunoglobulin A[24,25]. The composition of the colonic mucosal barrier is determined by the microbiota[26]. Symbiotic bacteria use various strategies to circumvent the intestinal immune system, including actively suppressing epithelial proinflammatory signaling pathways[25].

The gut microbiota has a close bidirectional relationship with the liver[27]. The liver is connected to the gut through the portal vein system, which carries blood from the gastrointestinal tract. This blood contains various substances, including bacterial lipopolysaccharide (LPS), that can significantly impact the liver's structure and function. The liver can also affect the gut microbiota through the enterohepatic circulation of bile acids[28]. Therefore, the gut-liver axis is a bidirectional communication and its disruption has important clinical implications. Alcoholic liver disease (ALD), non-ALD, and biliary tract diseases have been linked to changes in the gut microbiome. Alterations in the gut microbiome can affect the development and severity of liver steatosis, inflammation, and fibrosis through multiple interactions with immune and other cells[29].

In recent years, there has been an increased interest in the role of gut microbiota as a key factor in the development of liver steatosis. Metabolic-associated fat liver disease or non-alcoholic fatty liver disease (NAFLD) is an important medical problem and is of growing interest to clinicians and researchers[30,31]. NAFLD is characterized by the accumulation of excessive fat in the liver (steatosis) in patients who do not consume significant amounts of alcohol. The disease is thought to be caused by a complex interplay of internal and external factors, including nutritional disorders and disturbances in the gut microbiota structure. Changes in the gut microbiota have been associated with NAFLD and are dependent on the clinical stages of the disease[32,33]. The study found that disease progression corresponded with a decrease in microbiota diversity and an increase in Gram-negative bacteria, and a decrease in Gram-positive bacteria[33-35]. The development of a pro-inflammatory and metabolically toxic gut microbiota environment leads to disruption of the intestinal barrier, which increases the liver's exposure to negative nutritional and microbiota-related factors[33,36]. Increased permeability of the intestinal barrier to substances is a contributing factor in metabolic dysfunction-associated steatotic liver disease patients with fibrosis[37]. It is worth noting that bacterial DNAs were detected in the liver tissue of patients with NAFLD [38]. In patients with morbid obesity, Bacteroidetes and Firmicutes were more prevalent, while in patients without morbid obesity, mainly Proteobacteria were present. Additionally, the presence of Proteobacteria DNA was associated with lobular and portal inflammation scores[39].

Patients with ALD have increased intestinal permeability and elevated systemic levels of gut-derived microbial products[40]. Bacterial LPS contributes to inflammation in ALD through activation of Toll-like receptor 4[41,42].

The gut microbiota plays an important role in the progression of liver cirrhosis and the development of disease decompensation, including through bacterial translocation and inflammation[20,43]. The use of antibiotics is considered a treatment for complications of liver cirrhosis[20,44].

Dysbiosis of gut microbiota is also known to be associated with cholelithiasis[45]. Progression of cholelithiasis is characterized by changes in the bacterial community of bile, including a decrease in the number of Proteobacteria and an increase in the number of Firmicutes and Bacteroidota in groups of patients compared to healthy controls[46]. Bile acids may promote the growth of some bacteria that metabolize bile acids and at the same time inhibit the growth of other bacteria sensitive to bile[47]. In turn, the gut microbiota regulates the expression of several of the enzymes involved in bile acid formation, including CYP7A1, CYP7B1, and CYP27A1[47,48].

Thus, a growing body of evidence demonstrates the important role of the gut microbiota, making it a therapeutic target [49]. As diet is one of the key factors influencing changes in gut microbiota composition, dietary modification is an important component of the treatment of many diseases. In addition, exercise has a favorable effect on the gut microbiota profile[50-52]. There is a growing number of studies on fecal transplants, but their therapeutic potential is still unclear [53]. Studies on the potential use of probiotics for the prevention and treatment of liver disease are also of interest[54-56]. In general, despite a fairly large body of accumulated knowledge, there is currently no sufficiently convincing data on effective effects on the gut microbiota to achieve the goals of treatment and prevention of liver disease.

CONCLUSION

Thus, the gut microbiota is an important metabolic and immune "organ" that has close bidirectional links to liver function. The gut microbiota has extensive biological functions, many details of which are only beginning to be understood. Active study of the function of the gut microbiota in recent years has led to a better understanding of its role in the development and progression of various liver and biliary diseases. Obviously, studying only changes in the structure of the microbiota in various diseases and conditions is not able to answer all questions, since data on the ratio of bacteria do not provide an understanding of their functional activity. In addition, it may also be relevant that bacteria may change their activity in response to patients taking different medications. In this regard, pharmacomicrobiomics represents a promising new area of research[57,58]. It should also be noted that the therapeutic potential of the gut microbiota has limited application to date and is mainly related to dietary modification. In this regard, new studies of the gut microbiota-liver axis may be useful to improve approaches to the treatment of liver diseases.

FOOTNOTES

Author contributions: Kotlyarov S conceptualization, methodology, validation, resources, data curation, writing-original draft preparation, writing-review and editing, supervision, project administration.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: Russia

ORCID number: Stanislav Kotlyarov 0000-0002-7083-2692.

S-Editor: Qu XL

L-Editor: A

P-Editor: Cai YX

REFERENCES

- 1 **Tovani-Palone MR**, Pedersini P. Potential role of the microbiome in liver injury during COVID-19: Further research is needed. *World J Gastroenterol* 2023; **29**: 503-507 [PMID: 36688015 DOI: 10.3748/wjg.v29.i3.503]
- 2 **Novakovic M**, Rout A, Kingsley T, Kirchoff R, Singh A, Verma V, Kant R, Chaudhary R. Role of gut microbiota in cardiovascular diseases. *World J Cardiol* 2020; **12**: 110-122 [PMID: 32431782 DOI: 10.4330/wjc.v12.i4.110]
- 3 **Liu ZZ**, Sun JH, Wang WJ. Gut microbiota in gastrointestinal diseases during pregnancy. *World J Clin Cases* 2022; **10**: 2976-2989 [PMID: 35647135 DOI: 10.12998/wjcc.v10.i10.2976]
- 4 **Zyoud SH**, Shakhshir M, Abushanab AS, Koni A, Shahwan M, Jairoun AA, Abu Taha A, Al-Jabi SW. Unveiling the hidden world of gut health: Exploring cutting-edge research through visualizing randomized controlled trials on the gut microbiota. *World J Clin Cases* 2023; **11**:

- 6132-6146 [PMID: 37731574 DOI: 10.12998/wjcc.v11.i26.6132]
- 5 **Mafra D**, Ribeiro M, Fonseca L, Regis B, Cardozo LFMF, Fragoso Dos Santos H, Emiliano de Jesus H, Schultz J, Shiels PG, Stenvinkel P, Rosado A. Archaea from the gut microbiota of humans: Could be linked to chronic diseases? *Anaerobe* 2022; **77**: 102629 [PMID: 35985606 DOI: 10.1016/j.anaerobe.2022.102629]
 - 6 **Thursby E**, Juge N. Introduction to the human gut microbiota. *Biochem J* 2017; **474**: 1823-1836 [PMID: 28512250 DOI: 10.1042/BCJ20160510]
 - 7 **Hill DA**, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. *Annu Rev Immunol* 2010; **28**: 623-667 [PMID: 20192812 DOI: 10.1146/annurev-immunol-030409-101330]
 - 8 **Xu J**, Gordon JI. Honor thy symbionts. *Proc Natl Acad Sci U S A* 2003; **100**: 10452-10459 [PMID: 12923294 DOI: 10.1073/pnas.1734063100]
 - 9 **Bäckhed F**, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci U S A* 2004; **101**: 15718-15723 [PMID: 15505215 DOI: 10.1073/pnas.0407076101]
 - 10 **Savage DC**. Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol* 1977; **31**: 107-133 [PMID: 334036 DOI: 10.1146/annurev.mi.31.100177.000543]
 - 11 **Hsu CL**, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. *Nat Rev Microbiol* 2023; **21**: 719-733 [PMID: 37316582 DOI: 10.1038/s41579-023-00904-3]
 - 12 **Jasirwan COM**, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. *Biosci Microbiota Food Health* 2019; **38**: 81-88 [PMID: 31384519 DOI: 10.12938/bmfh.18-032]
 - 13 **Kotlyarov S**. Role of Short-Chain Fatty Acids Produced by Gut Microbiota in Innate Lung Immunity and Pathogenesis of the Heterogeneous Course of Chronic Obstructive Pulmonary Disease. *Int J Mol Sci* 2022; **23** [PMID: 35563159 DOI: 10.3390/ijms23094768]
 - 14 **Zheng L**, Wen XL, Duan SL. Role of metabolites derived from gut microbiota in inflammatory bowel disease. *World J Clin Cases* 2022; **10**: 2660-2677 [PMID: 35434116 DOI: 10.12998/wjcc.v10.i9.2660]
 - 15 **Tian P**, Yang W, Guo X, Wang T, Tan S, Sun R, Xiao R, Wang Y, Jiao D, Xu Y, Wei Y, Wu Z, Li C, Gao L, Ma C, Liang X. Early life gut microbiota sustains liver-resident natural killer cells maturation via the butyrate-IL-18 axis. *Nat Commun* 2023; **14**: 1710 [PMID: 36973277 DOI: 10.1038/s41467-023-37419-7]
 - 16 **Xu Z**, Jiang N, Xiao Y, Yuan K, Wang Z. The role of gut microbiota in liver regeneration. *Front Immunol* 2022; **13**: 1003376 [PMID: 36389782 DOI: 10.3389/fimmu.2022.1003376]
 - 17 **Hosoya S**, Ikejima K, Takeda K, Arai K, Ishikawa S, Yamagata H, Aoyama T, Kon K, Yamashina S, Watanabe S. Innate immune responses involving natural killer and natural killer T cells promote liver regeneration after partial hepatectomy in mice. *Am J Physiol Gastrointest Liver Physiol* 2013; **304**: G293-G299 [PMID: 23086918 DOI: 10.1152/ajpgi.00083.2012]
 - 18 **Wu X**, Sun R, Chen Y, Zheng X, Bai L, Lian Z, Wei H, Tian Z. Oral ampicillin inhibits liver regeneration by breaking hepatic innate immune tolerance normally maintained by gut commensal bacteria. *Hepatology* 2015; **62**: 253-264 [PMID: 25783863 DOI: 10.1002/hep.27791]
 - 19 **Lee NY**, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Jung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pedicoccus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. *Gut Microbes* 2020; **11**: 882-899 [PMID: 31965894 DOI: 10.1080/19490976.2020.1712984]
 - 20 **Lee NY**, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. *Int J Mol Sci* 2020; **22** [PMID: 33379148 DOI: 10.3390/ijms22010199]
 - 21 **Ley RE**, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006; **444**: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]
 - 22 **Prykhodko O**, Burleigh S, Campanello M, Iresjö BM, Zilling T, Ljungh Å, Smedh U, Hållenius FF. Long-Term Changes to the Microbiome, Blood Lipid Profiles and IL-6 in Female and Male Swedish Patients in Response to Bariatric Roux-en-Y Gastric Bypass. *Nutrients* 2024; **16** [PMID: 38398821 DOI: 10.3390/nu16040498]
 - 23 **Johansson ME**, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. *Proc Natl Acad Sci U S A* 2008; **105**: 15064-15069 [PMID: 18806221 DOI: 10.1073/pnas.0803124105]
 - 24 **Vaishnava S**, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, Ley R, Wakeland EK, Hooper LV. The antibacterial lectin RegIIIγ promotes the spatial segregation of microbiota and host in the intestine. *Science* 2011; **334**: 255-258 [PMID: 21998396 DOI: 10.1126/science.1209791]
 - 25 **Hooper LV**. Do symbiotic bacteria subvert host immunity? *Nat Rev Microbiol* 2009; **7**: 367-374 [PMID: 19369952 DOI: 10.1038/nrmicro2114]
 - 26 **Jakobsson HE**, Rodríguez-Piñero AM, Schütte A, Ermund A, Boysen P, Bemark M, Sommer F, Bäckhed F, Hansson GC, Johansson ME. The composition of the gut microbiota shapes the colon mucus barrier. *EMBO Rep* 2015; **16**: 164-177 [PMID: 25525071 DOI: 10.15252/embr.201439263]
 - 27 **Quesada-Vázquez S**, Aragonès G, Del Bas JM, Escoté X. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis. *Cells* 2020; **9** [PMID: 31936799 DOI: 10.3390/cells9010176]
 - 28 **Song Q**, Zhang X. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. *Biomedicines* 2022; **10** [PMID: 35327326 DOI: 10.3390/biomedicines10030524]
 - 29 **Tilg H**, Cani PD, Mayer EA. Gut microbiome and liver diseases. *Gut* 2016; **65**: 2035-2044 [PMID: 27802157 DOI: 10.1136/gutjnl-2016-312729]
 - 30 **Chen L**, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. *J Hepatol* 2024; **80**: e64-e66 [PMID: 37714381 DOI: 10.1016/j.jhep.2023.08.021]
 - 31 **Gofton C**, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? *Clin Mol Hepatol* 2023; **29**: S17-S31 [PMID: 36443926 DOI: 10.3350/cmh.2022.0367]
 - 32 **Pezzino S**, Sofia M, Mazzone C, Castorina S, Puleo S, Barchitta M, Agodi A, Gallo L, La Greca G, Latteri S. Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database. *Biology (Basel)* 2023; **12** [PMID: 37237476 DOI: 10.3390/biology12050662]
 - 33 **Hrnčir T**, Hrnčirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejssek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. *Microorganisms* 2021; **9** [PMID: 33946843 DOI: 10.3390/microorganisms9050957]
 - 34 **Woodhouse CA**, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. *Aliment Pharmacol Ther* 2018; **47**: 192-202 [PMID: 29083037 DOI: 10.1111/apt.14397]

- 35 **Loomba R**, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metab* 2017; **25**: 1054-1062.e5 [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001]
- 36 **Aron-Wisniewsky J**, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 279-297 [PMID: 32152478 DOI: 10.1038/s41575-020-0269-9]
- 37 **Forlano R**, Martinez-Gili L, Takis P, Miguens-Blanco J, Liu T, Triantafyllou E, Skinner C, Loomba R, Thursz M, Marchesi JR, Mullish BH, Manousou P. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus. *Gut Microbes* 2024; **16**: 2304157 [PMID: 38235661 DOI: 10.1080/19490976.2024.2304157]
- 38 **Sookoian S**, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycochea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. *Gut* 2020; **69**: 1483-1491 [PMID: 31900291 DOI: 10.1136/gutjnl-2019-318811]
- 39 **Lelouvier B**, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. *Hepatology* 2016; **64**: 2015-2027 [PMID: 27639192 DOI: 10.1002/hep.28829]
- 40 **Hartmann P**, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. *Alcohol Clin Exp Res* 2015; **39**: 763-775 [PMID: 25872593 DOI: 10.1111/acer.12704]
- 41 **Meroni M**, Longo M, Dongiovanni P. Alcohol or Gut Microbiota: Who Is the Guilty? *Int J Mol Sci* 2019; **20** [PMID: 31540133 DOI: 10.3390/ijms20184568]
- 42 **Szabo G**. Gut-liver axis in alcoholic liver disease. *Gastroenterology* 2015; **148**: 30-36 [PMID: 25447847 DOI: 10.1053/j.gastro.2014.10.042]
- 43 **Maslennikov R**, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? *World J Clin Cases* 2021; **9**: 9320-9332 [PMID: 34877269 DOI: 10.12998/wjcc.v9.i31.9320]
- 44 **Trebicka J**, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. *J Hepatol* 2021; **75** Suppl 1: S67-S81 [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013]
- 45 **Wu T**, Zhang Z, Liu B, Hou D, Liang Y, Zhang J, Shi P. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. *BMC Genomics* 2013; **14**: 669 [PMID: 24083370 DOI: 10.1186/1471-2164-14-669]
- 46 **Cai X**, Peng Y, Gong Y, Huang X, Liu L, Chen Y, Du J, Dai Z, Qian Y, Xu L. Variations of bile bacterial community alongside gallstone disease progression and key taxa involved in poor outcomes after endoscopic surgery. *Eur J Med Res* 2023; **28**: 313 [PMID: 37660138 DOI: 10.1186/s40001-023-01308-y]
- 47 **Wahlström A**, Sayin SI, Marschall HU, Bäckhed F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metab* 2016; **24**: 41-50 [PMID: 27320064 DOI: 10.1016/j.cmet.2016.05.005]
- 48 **Sayin SI**, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab* 2013; **17**: 225-235 [PMID: 23395169 DOI: 10.1016/j.cmet.2013.01.003]
- 49 **Nishida A**, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, Imaeda H. Update on gut microbiota in gastrointestinal diseases. *World J Clin Cases* 2022; **10**: 7653-7664 [PMID: 36158494 DOI: 10.12998/wjcc.v10.i22.7653]
- 50 **Monda V**, Villano I, Messina A, Valenzano A, Esposito T, Moscatelli F, Viggiano A, Cibelli G, Chieffi S, Monda M, Messina G. Exercise Modifies the Gut Microbiota with Positive Health Effects. *Oxid Med Cell Longev* 2017; **2017**: 3831972 [PMID: 28357027 DOI: 10.1155/2017/3831972]
- 51 **Clauss M**, Gérard P, Mosca A, Leclerc M. Interplay Between Exercise and Gut Microbiome in the Context of Human Health and Performance. *Front Nutr* 2021; **8**: 637010 [PMID: 34179053 DOI: 10.3389/fnut.2021.637010]
- 52 **Dziewiecka H**, Buttar HS, Kasperska A, Ostapiuk-Karolczuk J, Domagalska M, Cichoń J, Skarpańska-Stejnborn A. Physical activity induced alterations of gut microbiota in humans: a systematic review. *BMC Sports Sci Med Rehabil* 2022; **14**: 122 [PMID: 35799284 DOI: 10.1186/s13102-022-00513-2]
- 53 **Kruger-Sharabi O**, Malnick SDH, Fisher D. Manipulation of the intestinal microbiome-a slow journey to primetime. *World J Clin Cases* 2023; **11**: 4975-4988 [PMID: 37583860 DOI: 10.12998/wjcc.v11.i21.4975]
- 54 **Forlano R**, Sivakumar M, Mullish BH, Manousou P. Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. *Int J Mol Sci* 2022; **23** [PMID: 35955434 DOI: 10.3390/ijms23158307]
- 55 **Han TR**, Yang WJ, Tan QH, Bai S, Zhong H, Tai Y, Tong H. Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials. *Front Microbiol* 2022; **13**: 1004911 [PMID: 36726574 DOI: 10.3389/fmicb.2022.1004911]
- 56 **Wan MLY**, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. *Hepatobiliary Surg Nutr* 2018; **7**: 11-20 [PMID: 29531939 DOI: 10.21037/hbsn.2017.12.07]
- 57 **Pant A**, Maiti TK, Mahajan D, Das B. Human Gut Microbiota and Drug Metabolism. *Microb Ecol* 2023; **86**: 97-111 [PMID: 35869999 DOI: 10.1007/s00248-022-02081-x]
- 58 **Dikeocha IJ**, Al-Kabsi AM, Miftahussurur M, Alshawsh MA. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. *FASEB J* 2022; **36**: e22350 [PMID: 35579628 DOI: 10.1096/fj.202101986R]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

